Eckert & Ziegler AG to Acquire f-con Europe GmbH
Ad hoc announcement §15 WpHG Acquisitions Eckert & Ziegler AG to Acquire f-con Europe GmbH Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement.
Berlin, 30.06.2005.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in radioactive components for medical and in- dustrial use will acquire 51% of the shares of f-con Europe GmbH, as of July 1, 2005. In order to differentiate from the Austrian f-con group the com- pany's name will be changed to Eckert & Ziegler f-con Europe GmbH. The Hesse based company distributes radioactive glucose (PET tracer) through its subsidiaries in Germany and Italy. The radioactive glucose is used to di- agnose cancer with the so called Positron Emission Tomography (PET). In 2004 the company achieved sales of approximately 3 Mio EUR. The general manager of Eckert & Ziegler f-con Europe GmbH will be Axel Schmidt, a radio chemist with long standing expert knowledge, who brings an experienced team into the group.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0)30 / 94 10 84-138
http://www.ezag.de
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10 13125 Berlin Deutschland
ISIN: DE0005659700
WKN: 565970
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
End of ad hoc announcement
(c)DGAP 30.06.2005 301202 Jun 05
Berlin, 30.06.2005.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist in radioactive components for medical and in- dustrial use will acquire 51% of the shares of f-con Europe GmbH, as of July 1, 2005. In order to differentiate from the Austrian f-con group the com- pany's name will be changed to Eckert & Ziegler f-con Europe GmbH. The Hesse based company distributes radioactive glucose (PET tracer) through its subsidiaries in Germany and Italy. The radioactive glucose is used to di- agnose cancer with the so called Positron Emission Tomography (PET). In 2004 the company achieved sales of approximately 3 Mio EUR. The general manager of Eckert & Ziegler f-con Europe GmbH will be Axel Schmidt, a radio chemist with long standing expert knowledge, who brings an experienced team into the group.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0)30 / 94 10 84-138
http://www.ezag.de
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10 13125 Berlin Deutschland
ISIN: DE0005659700
WKN: 565970
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
End of ad hoc announcement
(c)DGAP 30.06.2005 301202 Jun 05